Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HepNet Acute HCV-V Study
NCT03818308Phase 2Completed
- Sponsor
- Hannover Medical School
- Start
- May 2019
- Primary completion
- Jun 2021
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of velpatasvir in hepatitis C virus infection, sponsored by Hannover Medical School. Primary endpoint: Sustained Virological Response at 12 Weeks. Started May 2019; status: completed.
02
Drugs
velpatasvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT03818308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03818308.